After 24 weeks ' treatment , the 0.5-mg dose demonstrated minimal efficacy ( HbA1c -0.3 0.12 % ) and the 2-mg dose demonstrated near-maximal efficacy ( HbA1c -1.1 0.12 % ) , which was not statistically different from the efficacy of 45 mg pioglitazone ( HbA1c -0.9 0.12 % ; P < 0.01 for noninferiority ) .